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Abstract Akt is activated by growth factors to regulate vari-
ous aspects of vascular smooth muscle cell function. Platelet-
derived growth factor (PDGF) and insulin-like growth factor-1
activated Akt in vascular smooth muscle cells with a rapid re-
duction of total Akt protein that lasted for several hours. The
downregulation of Akt required phosphatidylinositol 3-kinase
activity, but not intrinsic Akt activity. The downregulation of
Akt was abrogated by MG-132, a proteasome inhibitor, but not
by inhibitors of calpain or cathepsins. Akt was found in ubiq-
uitin immune complex after PDGF treatment. Proteasome-de-
pendent degradation of Akt may provide a counter-regulatory
mechanism against overactivation of Akt.
( 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Vascular smooth muscle cells (VSMCs) are a principal cell
type of blood vessels that are essential not only for physio-
logical function of vasculature but are also involved in the
pathophysiology of atherosclerosis and hypertension. In the
last decade, extensive e¡orts have been made to elucidate the
molecular mechanisms underlying pathophysiological re-
sponses in VSMCs to identify key signaling pathways includ-
ing the mitogen-activated protein kinase (see [1] for review),
NF-UB [2] and phosphatidylinositol 3-kinase (PI3-kinase)/Akt
(also known as protein kinase B) pathways [3^7]. Among
these, the PI3-kinase/Akt pathway participates in a wide range
of cellular functions such as amino acid metabolism [3], cell
survival [4], migration [5,6], proliferation [5,6] and di¡erentia-
tion [8] of VSMCs and other cell types (see [9,10] for recent
review). Akt is known to be activated in VSMCs by various
growth factors such as platelet-derived growth factor (PDGF)
[11,12] and insulin-like growth factor-1 (IGF-1) [13] that are
implicated in VSMC migration and proliferation in athero-
sclerosis (see [14] for review). While much is known of the
activation of Akt in response to growth factor stimulation,
the mechanisms to deactivate Akt are little understood. This
prompted us to characterize the mechanism of Akt deactiva-
tion following PDGF stimulation in VSMCs. Unexpectedly,
PDGF caused a rapid decrease in Akt protein levels concom-
itant with Akt activation. We provide evidence that PDGF
causes regulated proteolytic downregulation of Akt that is
dependent on PI3-kinase and proteasome activities. Protea-
some-dependent downregulation of Akt may be a fundamen-
tal mechanism to regulate the activity and function of Akt in
VSMCs.
2. Materials and methods
2.1. Cell culture
VSMCs were obtained from the aorta of 8-week-old male Wistar
rats by enzyme dispersion as described previously [15]. Brie£y, aortae
were dissected under sterile conditions. After removing adventitia and
endothelium, the aortic medial layer was minced with scissors
and dispersed by incubating with 1 mg/ml collagenase (Sigma) and
10 U/ml elastase (Sigma) for 100 min at 37‡C. Dispersed cells were
plated and maintained in Dulbecco’s modi¢ed Eagle medium (Invi-
trogen) containing 10% fetal bovine serum on culture plates coated
with 20 Wg/ml laminin. All experiments were performed using cells
between passages 2 and 5. Con£uent VSMCs were serum-starved
for 24 h before experiments. The animal experimental protocol has
been approved by the Yamaguchi University School of Medicine An-
imal Review Board. COS7, HEK293 and NIH3T3 cells were main-
tained in Dulbecco’s modi¢ed Eagle medium containing 10% newborn
calf serum (Invitrogen).
2.2. Cell culture experiments
For transient transfection, COS7 cells were transfected with pU-
SEamp-Myc-Akt(KM) expression plasmid encoding kinase-inactive
Akt with a c-Myc epitope tag (Upstate Biotechnology) using FuGene6
(Roche). One plate of transfected cells was split into four plates and
serum-starved for 24 h, followed by stimulation with (two plates) or
without (two plates) 20 ng/ml IGF-1 (Sigma) for 10 min. Exogenous
Akt(KM) was detected by Western blotting for the Myc epitope tag.
For inhibition of PI3-kinase, VSMCs were treated with various con-
centrations of LY294002 (Sigma) 30 min before and during stimula-
tion with 10 ng/ml PDGF (Invitrogen). For inhibition of protein syn-
thesis, VSMCs were treated with 20 WM cycloheximide (Wako) for the
indicated periods. For the inhibition of proteases, VSMCs were
treated with various concentrations of MG-132 (Biomol), ALLN
(Calbiochem), CA-074Me (Biomol), E-64-d (Peptide Institute) or ve-
hicle (0.1% dimethyl sulfoxide) for 2 h before and during stimulation
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with PDGF. After stimulation with 10 ng/ml PDGF or 20 ng/ml
IGF-1 for the indicated periods, cells were harvested and subjected
to further analysis as described below.
2.3. Immunoprecipitation and Western blotting
For immunoprecipitation of ubiquitinated proteins, cells were har-
vested in lysis bu¡er containing 20 mM Tris (pH 7.4), 1% Triton
X-100, 150 mM NaCl, 1 mM Na3VO4, 10 mM NaF, 10 mM sodium
pyrophosphate, 10 mM L-glycerophosphate, 0.5 mM EGTA, 1 mM
phenylmethylsulfonyl £uoride, 10 Wg/ml aprotinin, 100 WM leupeptin
and 1 mM dithiothreitol. After clarifying the lysate by centrifugation
(18 000Ug, 15 min at 4‡C), 500 Wl of cell lysates containing equal
amounts of proteins were subjected to immunoprecipitation by incu-
bating with 5 Wg each of two anti-ubiquitin monoclonal antibodies
(clones #1B3 and #2C5, Medical and Biological Laboratories) over-
night at 4‡C, followed by incubation with protein G-Sepharose (Sig-
ma) for 3 h at 4‡C. After washing with lysis bu¡er, immunoprecipi-
tated proteins were resolved on 10% or 7.5% sodium dodecyl sulfate^
polyacrylamide gel electrophoresis (SDS^PAGE), transferred to poly-
vinylidene di£uoride (PVDF) membrane, and subjected to Western
blot analyses. For direct Western blotting analyses, cells were har-
vested in boiling SDS sample bu¡er containing 2% SDS, 50 mM
Tris (pH 6.8), 10% glycerol and 5% 2-mercaptoethanol to obtain total
cell lysates. Proteins were resolved on 9% SDS^PAGE and transferred
to PVDF membranes. Total Akt was detected by anti-Akt polyclonal
(Cell Signaling Technology) or monoclonal (Transduction Laborato-
ries) antibodies. Active Akt was detected by anti-phospho-Akt
(Ser473) or phospho-Akt (Thr308) polyclonal antibodies (Cell Signal-
ing Technology). Ubiquitin was detected by anti-ubiquitin monoclo-
nal antibodies (clones #1B3 and #2C5). Western blotting of glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) with a monoclonal
antibody (Chemicon) served as a control for protein loading. Probed
proteins were visualized by chemiluminescence (Super Signal, Pierce)
and luminoimaging (LAS-1000, Fuji Film).
2.4. Statistical analysis
All data are expressed as meansSS.E.M. Statistical analyses were
performed using analysis of variance. The post-test comparison was
performed by the method of Bonferroni. P values of 6 0.05 were
accepted to be signi¢cant.
3. Results and discussion
3.1. PDGF causes activation of Akt and a decrease in
Akt protein
We characterized the time course of Akt activation by
PDGF in VSMCs. Active Akt was detected by a phosphospe-
ci¢c antibody that recognizes phosphorylation of Akt at
Ser473. As shown in Fig. 1A,B, Akt was rapidly activated
(phosphorylated) by PDGF within 1 min, peaked at 10 min
and remained active for at least 120 min (91% of the peak
activation at 120 min). Western blotting with a phosphospe-
ci¢c antibody for Thr308 phosphorylation of Akt gave iden-
tical results (data not shown). Interestingly, the amount of
total Akt, which was detected using polyclonal antibodies
for C-terminus of Akt, rapidly decreased upon its activation.
The amount of total Akt reached its lowest level, 23% of the
initial level, at 30 min and then gradually recovered to 48% of
the initial level at 120 min. Equal loading of proteins was
con¢rmed by Western blotting for GAPDH (Fig. 1A). We
also used a monoclonal antibody raised against the N-termi-
nal half (Fig. 1C) or PH domain (data not shown) of Akt to
con¢rm this result. As shown in Fig. 1C, both the C-terminus-
and N-terminus-speci¢c Akt antibodies detected the decrease
in Akt protein upon stimulation with PDGF. Translocation of
Akt in the cell is unlikely to account for these ¢ndings because
the lysis conditions should disrupt the cytoarchitecture and
solubilize the proteins. Therefore, we concluded that total
Akt detected by Western blotting re£ects the actual amount
of Akt protein in the cell, which decreased following its acti-
vation by PDGF stimulation.
3.2. Signaling for the activation of and decrease in Akt
We next asked whether the decrease in Akt protein levels is
speci¢c for PDGF stimulation. IGF-1 is a well-characterized
activator of the Akt pathway. As shown in Fig. 2A, IGF-1
activated Akt in VSMCs at 10 min, which was accompanied
by the decrease in total Akt protein levels. Therefore, activa-
tion of Akt by both PDGF and IGF-1 is accompanied by a
decrease in total Akt protein in VSMCs. Both PDGF and
IGF-1 activate PI3-kinase, as well as other signaling path-
ways. We examined whether activation of PI3-kinase is neces-
sary for the decrease in Akt protein. As shown in Fig. 2B,C,
treatment of VSMCs with LY294002, a speci¢c inhibitor of
PI3-kinase, diminished both Akt activation and the decrease
in Akt protein in a dose-dependent manner. Interestingly,
20 WM LY294002 completely abolished the decrease in Akt
protein by PDGF, but only partially suppressed Akt activa-
tion (45S 3% of the activation without LY294002, P6 0.0001
compared with PDGF alone, n=4). Akt protein decreased
to 39S 4% of the initial level by PDGF stimulation with-
out LY294002 (P6 0.0001 compared with control, n=4)
whereas it remained at control levels in the presence of
20 WM LY294002 (101S 22%; P=0.95 compared with con-
trol, n=4). Therefore, although both activation of Akt and
the decrease in Akt protein depend on PI3-kinase activity,
the latter is more sensitive to PI3-kinase inhibition. These
results suggest that activation of Akt per se is not su⁄cient
for the decrease in Akt protein and another PI3-kinase-depen-
Fig. 1. PDGF activates Akt and decreases Akt protein levels.
A: VSMCs were stimulated with 10 ng/ml PDGF for the indicated
periods. Phosphorylated (active) Akt (P-Akt) and total Akt were de-
tected by Western blotting. Western blotting for GAPDH is shown
as a control for protein loading. B: Densitometric analysis of total
Akt (open circles) and active Akt (closed squares) is shown. The rel-
ative signal intensities are shown where the peak signal is designated
100% for each Western analysis. Representative results of at least
three independent observations are shown. C: Western analyses
were performed after PDGF (10 ng/ml) stimulation for 10 min using
polyclonal (pAb) and monoclonal (mAb) antibodies for total Akt,
and phosphorylated (active) Akt (P-Akt) antibody. Representative
results from at least four independent observations are shown.
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dent mechanism may participate in the decrease in Akt
protein.
The activation-dependent decrease in Akt protein was not
limited to VSMCs, because it was also observed in other cell
types including COS7 (Fig. 2D), HEK293 and NIH3T3 cells
(data not shown), suggesting that there may be universal mo-
lecular mechanisms that regulate total Akt protein levels fol-
lowing its activation regardless of cell type. We examined
whether intrinsic kinase activity of Akt is necessary for its
downregulation by utilizing a catalytically inactive Akt mu-
tant with a Myc epitope tag (Akt(KM)). Akt(KM) was ex-
pressed in COS7 cells by transient transfection and protein
levels were detected by Western blotting for the Myc epitope
tag. As shown in Fig. 2E,F, exogenously expressed Akt(KM)
protein also underwent downregulation in response to IGF-1
treatment. Therefore, intrinsic kinase activity of Akt is dis-
pensable for its downregulation.
3.3. Proteasome-dependent downregulation of Akt
The rapid decrease in the amount of Akt suggested that Akt
may be proteolytically degraded upon PDGF or IGF-1 stim-
ulation rather than transcriptionally or translationally sup-
pressed. To test this, we screened an array of protease inhib-
itors for an e¡ect on PDGF-induced decrease in Akt. The
protease inhibitors included MG-132 (proteasome), ALLN
(calpain), CA-074Me (cathepsin B) and E-64-d (cathepsin B/
H/L and calpain). Treatment of VSMCs with each of these
protease inhibitors did not change basal levels of Akt protein
nor Akt activation by PDGF. Among the inhibitors, MG-132,
a proteasome inhibitor, caused a signi¢cant increase in Akt
after PDGF stimulation (Fig. 3A). As shown in Fig. 3B, Akt
levels after PDGF stimulation were 26S 3% (n=4) of the
basal level without MG-132 treatment, 36S 3% (n=4) with
10 WM MG-132 and 56S 1% (P6 0.001 compared with con-
trol, n=4) with 100 WM MG-132. Stability of Akt protein at
the basal condition was assessed by treating VSMCs with
cycloheximide to inhibit de novo protein synthesis. As shown
in Fig. 3C, treatment of VSMCs with cycloheximide for 2 h
minimally a¡ected the basal level of Akt, indicating that Akt
is relatively stable during this observation period. Treatment
of VSMCs with cycloheximide and MG-132 also had little
e¡ect on Akt protein level. These results indicate that protea-
some activity is responsible, at least in part, for the PDGF-
induced decrease in Akt protein. In addition, a proteasome-
dependent mechanism seems to be activated by PDGF to
downregulate Akt, because MG-132 had little e¡ect on the
level of Akt protein in unstimulated cells in the absence or
presence of cycloheximide.
We next examined whether PDGF promotes protein ubiq-
uitination in VSMCs. Ubiquitinated proteins were immuno-
precipitated by anti-ubiquitin monoclonal antibodies followed
by Western blotting for ubiquitin or Akt. As shown in Fig.
3D, very few ubiquitinated proteins were detected in VSMCs
with or without PDGF stimulation (lanes 1 and 2). However,
several bands were detected in VSMCs treated with 100 WM
MG-132, a proteasome inhibitor (lane 3, arrowheads). Inter-
estingly, PDGF stimulation caused an increase in the intensity
of multiple bands (lane 4, arrowheads), indicating that PDGF
stimulates ubiquitination of multiple proteins in VSMCs. Akt
was barely detectable in the ubiquitin immune complex in the
absence of MG-132 (Fig. 3E, lanes 1 and 2). However, in the
presence of MG-132, the ubiquitin immune complex con-
tained Akt which increased in response to PDGF stimulation
(Fig. 3E, lanes 3 and 4). Akt was not detected when immu-
noprecipitation was performed without primary antibody or
with irrelevant anti-FLAG antibody (data not shown), con-
¢rming the speci¢city of the signal. However, anti-ubiquitin
Western blot following Akt immunoprecipitation failed to
demonstrate direct ubiquitination of Akt (data not shown).
Therefore, Akt may make a multimolecular complex with un-
known molecule(s) that is ubiquitinated in response to PDGF
stimulation.
Our observations indicate that PDGF and IGF-1 cause
activation of Akt concomitant with a decrease in Akt protein
in VSMCs and other cell types. Expression levels of a number
of proteins are regulated by proteolytic degradation in a PI3-
kinase/Akt-dependent manner. These include insulin receptor
substrate (IRS) 1 [16^18], IRS-2 [19], p27Kip1 [20], IUB [21],
p53 [22], androgen receptor [23], FOXO3a and tuberin [24].
Our data indicate that Akt is another target of the regulated
Fig. 2. PDGF-induced decrease in Akt requires PI3-kinase activity
but not intrinsic Akt kinase activity. A: Total Akt and phosphory-
lated Akt (P-Akt) were probed with corresponding polyclonal anti-
bodies after 20 ng/ml IGF-1 stimulation for the indicated periods.
B: Total Akt and phosphorylated Akt (P-Akt) were detected by
Western blotting before and after 10 ng/ml PDGF stimulation for
10 min in the presence of various concentrations of LY294002
(LY). C: Quantitative analyses of experiment B are shown. Total
Akt levels are indicated by open columns where basal expression
levels are designated 100%. Phosphorylated Akt is indicated by
closed columns where signal intensity after PDGF stimulation
without LY294002 is designated 100%. Data are meansSS.E.M.
obtained from four independent observations. **P6 0.01,
***P6 0.001 compared with control (without PDGF or LY294002),
respectively. 2P6 0.05, 222P6 0.001 compared with PDGF alone.
D: COS7 cells were stimulated with 20 ng/ml IGF-1 for 10 min.
Akt and phosphorylated Akt (P-Akt) were detected by Western
blotting. E: COS7 cells were transiently transfected with an expres-
sion plasmid encoding kinase-inactive Akt with a c-Myc epitope tag
(Myc-Akt(KM)). Experiments were performed as described in Sec-
tion 2. Myc-Akt(KM) was detected by Myc Western blotting.
GAPDH Western blotting served as a control for protein loading.
F: Quantitative analysis of E is shown. Myc-Akt(KM) levels are in-
dicated as relative to the basal expression level which was desig-
nated 100%. Data are meansSS.E.M. from three independent ob-
servations. *P6 0.05 compared with control.
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degradation in response to growth factor stimulation. In fact,
Akt has been reported to be degraded in a proteasome-depen-
dent manner when HSP90 was inhibited [25]. However, our
results suggest that Akt may not be directly polyubiquitinated
but may be bound to an unknown molecule that is ubiquiti-
nated in response to PDGF stimulation. Since PDGF pro-
moted ubiquitination of a number of molecules, Akt may be
bound to one of these ubiquitinated molecules which may
bring Akt to the proteasome degradation machinery.
Akt has been reported to participate in the control of cell
survival, growth and di¡erentiation of VSMCs [4^6,8]. Ago-
nist-induced proteasome-dependent downregulation of Akt
protein may provide an important counter-regulatory mecha-
nism by which overactivation of Akt is blunted in growth
factor-rich conditions such as vascular injury and athero-
sclerosis [11,13]. Further characterization of the regulated
degradation of Akt will reveal the molecular mechanism of
its proteasome-dependent downregulation and provide a fun-
damental understanding of this potential counter-regulatory
mechanism induced by growth factors.
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Fig. 3. Proteasome-dependent decrease in Akt protein. A: Western
blotting for total Akt was performed before and after PDGF stimu-
lation in the presence or absence (C, control) of dimethyl sulfoxide
(V, vehicle), MG-132 (proteasome inhibitor), ALLN (calpain inhibi-
tor), CA-074Me (cathepsin B inhibitor) and E-64-d (cathepsin B/H/
L and calpain inhibitor). Densitometric analysis of the experiment is
shown. Signal intensities of total Akt after PDGF stimulation are
indicated as relative to those before PDGF stimulation, which is
designated 100%. B: Quantitative analyses are shown for Akt level
after PDGF stimulation in the presence of various concentrations of
MG-132. MeansSS.E.M. from four independent observations are
shown. ***P6 0.001 compared with control. C: Akt protein stabil-
ity was assessed by treating VSMCs with 20 WM cycloheximide
(CHX) with or without 100 WM MG-132 for 2 h. The Akt protein
amount is shown relative to the control level without cycloheximide
or MG-132 (Cont, open column), which is designated 100%. Data
are meansSS.E.M. of four observations. D,E: Immunoprecipitation
was performed with anti-ubiquitin antibodies in the presence or ab-
sence of PDGF and MG-132. Ubiquitinated proteins (D, arrow-
heads) or Akt (E, arrow) were detected with anti-ubiquitin or anti-
Akt antibodies, respectively. (H) indicates IgG heavy chain. Another
independent observation gave an identical result.
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